{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16","upperLimit":"48","value":"32"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Pathological response rate following neoadjuvant chemotherapy was assessed by TNM staging at the time of radical cystectomy","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and cisplatin IV on day 1 or divided over days 1 and 2. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-8 weeks after chemotherapy, patients undergo radical cystectomy.\n\ngemcitabine hydrochloride: Given IV\n\ncisplatin: Given IV\n\ntherapeutic conventional surgery: Undergo radical cystectomy\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Gemcitabine Hydrochloride, Cisplatin, Surgery)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Pathological Complete Response Rate Following Chemotherapy Before Surgery","type":"PRIMARY","unitOfMeasure":"percentage of participants"}